The future of obesity research

Nutrition

Volumn 16, Issue 10, 2000, Pages 976-982

  Greenway, Frank L ^a   Smith, Steven R ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Future; History; Molecular biology; Obesity; Physiology; Research

Indexed keywords

ANTIOBESITY AGENT;

ADIPOSE TISSUE; BODY COMPOSITION; BODY FAT; CHRONIC DISEASE; CONFERENCE PAPER; ENERGY EXPENDITURE; FOOD INTAKE; HISTORY; HUMAN; MEDICAL RESEARCH; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; WEIGHT REDUCTION;

CHRONIC DISEASE; HUMAN; OBESITY; RESEARCH; WEIGHT LOSS;

EID: 0033776838     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(00)00406-8     Document Type: Conference Paper

References (90)

1. William Osler at 150. An overview of a life
2. Health implications of obesity. National Institutes of Health Consensus Development Conference Statement
3. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report
4. Nach pancreas extirpation
5. Direct myocardial revascularization with saphenous vein autograft. Clinical experience in 100 cases
6. Treatment of hypertensive vascular disease with rice diet
7. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy
8. The effects of sympathectomy upon the mortality and survival rates of patients with hypertensive cardiovascular disease
9. Reevaluation of thoracic sympathectomy for the management of malignant hypertension
10. Long-term effects of pancreatic transplant function in patients with advanced juvenile-onset diabetes
11. Good outcomes from cardiac surgery in the over 70s
12. Effects of coronary artery bypass grafting using internal mammary arteries for diabetic patients
13. Surgical treatment of obesity
14. The partial ileal bypass operation in treatment of the hyperlipidemias
15. Gastrointestinal surgery for severe obesity
16. Evolution of the treatment of hypertension from the 1940s to JNC V
17. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation
18. Dinitrophenol. Its therapeutic and toxic actions in certain types of psychobiologic underactivity
19. Amphetamine addition
20. Aminorex, dexfenfluramine, and primary pulmonary hypertension
21. Valvular heart disease associated with fenfluramine-phentermine
22. Sibutramine produces dose-related weight loss
23. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group
24. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
25. Weight loss increases and fat loss decreases all-cause mortality rate; results from two independent cohort studies
26. The relationship between body weight and mortality; a quantitative analysis of combined information from existing studies
27. Regional adiposity and morbidity
28. Weight-reducing effects of the plasma protein encoded by the obese gene
29. Clinical review 94. What's in a name? In search of leptin's physiologic role
30. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
31. The human obesity gene map; the 1999 update
32. Effects of a traditional lifestyle on obesity in Pima Indians
33. The Gln27Glu polymorphism in the beta2-adrenergic receptor gene is not associated with morbid obesity in Austrian women
34. Structure, and function of the beta 3-adrenergic receptor
35. Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents
36. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes
37. Clinical review 90. Leptin and clinical medicine; a new piece in the puzzle of obesity
38. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers
39. Sibutramine in weight control; a dose-ranging, efficacy study
40. Sibutramine; a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine
41. Lipoprotein disorders as related to atherosclerotic cardiovascular disease
42. Chemical pathology of homocysteine. I. Atherogenesis
43. Etiology, and pathogenesis of obesity
44. Mood stabilization and weight loss with topiramate
45. Bupropion SR shows promise as an effective obesity treatment
46. The long-term effects of gastric pacing on an obese young woman
47. Gastric myo-electrical pacing as therapy for morbid obesity; preliminary results
48. Enterostatin-a peptide regulating fat intake
49. Oleoyl-estrone induces the loss of body fat in rats
50. Adenovirus that induces adiposity in animals also influences invitro differentiation of preadipocytes
51. Obesity induced by a human adenovirus can be transmitted by blood transfusion in chickens
52. Association of adenovirus infection with human obesity
53. Identification of Cd36 (fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats
54. Serial analysis of gene expression
55. Parallel human genome analysis; microarray-based expression monitoring of 1000 genes
56. Proteomics, and nutrition-a science for the first decade of the new millennium
57. Mass spectrometry. From genomics to proteomics
58. The transcriptional program in the response of human fibroblasts to serum
59. Genome-wide search for genes related to the fat-free body mass in the Quebec family study
60. Sensitivity to dietary obesity linked to a locus on chromosome 15 in a CAST/Ei x C57BL/6J F2 intercross
61. Positional cloning of the mouse obese gene and its human homologue
62. Genotype-based screen for ENU-induced mutations in mouse embryonic stem cells
63. Mouse mutants from chemically mutagenized embryonic stem cells
64. Role of hypothalamic neuropeptide Y in feeding and obesity
65. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member
66. Pharmacogenomics
67. Genetic mutations that predict weight loss in an obesity treatment program
68. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis
69. Drug target validation and identification of secondary drug target effects using DNA microarrays
70. Visceral adipose tissue; a critical review of intervention strategies
71. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries; a report from the Regression Growth Evaluation Statin Study
72. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes
73. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes
74. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease
75. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
76. Taste preferences and food intake
77. The food craving inventory and implications for weight loss treatment
78. Universal eating monitor for continuous recording of solid or liquid consumption in man
79. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans
80. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
81. Glucose-induced thermogenesis in postobese women who have undergone biliopancreatic diversion
82. Fasting respiratory quotient as a predictor of weight changes in non-obese women
83. Fasting respiratory exchange ratio and resting metabolic rate as predictors of weight gain; the Baltimore Longitudinal Study on Aging
84. The respiratory quotient as a prognostic factor in weight-loss rebound
85. Role of nonexercise activity thermogenesis in resistance to fat gain in humans